Tag: Exxua

According to the World Health Organization, depression is a leading cause of disability worldwide, affecting over 280 million people. For those with major depressive disorder (MDD) or other forms of the condition, newer medications like Exxua and Zurzuvae offer innovative treatment options and represent a shift towards targeting new biological pathways beyond traditional monoamines.

Following a lengthy and controversial development process, the FDA approved gepirone extended-release (Exxua) in September 2023 for major depressive disorder. While both gepirone and buspirone (Buspar) belong to the same azapirone class of medications, there are several key distinctions in **how is gepirone different from buspirone?**.

Approved by the FDA in 2023 after a multi-decade journey, gepirone (marketed as Exxua) offers a new treatment option for adults with major depressive disorder (MDD). Discover what class of medication is gepirone and how its novel mechanism of action sets it apart from more traditional antidepressants.

Gepirone, recently approved by the FDA for treating major depressive disorder (MDD) in adults, operates with a unique pharmacological approach compared to many other antidepressants. As a member of the azapirone class, **what is the mechanism of action of gepirone** involves the selective modulation of serotonergic activity in the brain, offering a novel treatment option for mood disorders.

In September 2023, the U.S. Food and Drug Administration (FDA) approved Exxua (gepirone extended-release) for the treatment of major depressive disorder (MDD) in adults. This marked a significant milestone, introducing a novel class of oral antidepressants into the market that functions differently than many existing options like selective serotonin reuptake inhibitors (SSRIs).

In 2021, an estimated 21 million adults in the United States—representing 8.3% of the adult population—experienced at least one major depressive episode [1.7.1]. For those seeking treatment, a critical question is: **What are the newest most effective antidepressants?**